nach oben

Tumor Biology

Erschienen in:

01.01.2014 | Research Article

GSTM1 null polymorphisms and oral cancer risk: a meta-analysis

verfasst von: Su-Feng Zhao, Xu-Dong Yang, Ming-Xing Lu, Guo-Wen Sun, Yu-Xin Wang, Yin-Kai Zhang, Yu-Mei Pu, En-Yi Tang

Erschienen in: Tumor Biology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Many studies have examined the association between the GSTM1 null gene polymorphism and oral cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. The PubMed and Embase databases were searched for case–control studies published up to May 2013. Data were extracted and pooled odds ratio (OR) with 95 % confidence intervals (CI) were calculated. Ultimately, 39 studies, comprising of 4,704 oral cancer cases and 7,090 controls, were included. Overall, for null versus present, the pooled OR was 1.29 (95 % CI = 1.20–1.40), and the heterogeneity was found in all studies. In the stratified analysis by ethnicity, significant risks were found among Asians (OR = 1.39, 95 % CI = 1.27–1.53; P = 0.000 for heterogeneity), but not in Caucasians (OR = 0.99, 95 % CI = 0.83–1.18; P = 0.677 for heterogeneity). In conclusion, this meta-analysis demonstrates that the GSTM1 null gene polymorphism may be an increased risk of oral cancer in Asians but not in Caucasians.

Zygogianni AG, Kyrgias G, Karakitsos P, Psyrri A, Kouvaris J, Kelekis N, et al. Oral squamous cell cancer: early detection and the role of alcohol and smoking. Head Neck Oncol. 2011;3:2.PubMedCentralPubMedCrossRef

Reichart PA, Nguyen XH. Betel quid chewing, oral cancer, and other oral mucosal diseases in Vietnam: a review. J Oral Pathol Med. 2008;37:511–4.PubMedCrossRef

Hirvonen A. Genetic factors in individual responses to environmental exposures. J Occup Environ Med. 1995;37:37–43.PubMedCrossRef

Bolt HM, Thier R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab. 2006;7:613–28.PubMedCrossRef

Wang Y, Spitz MR, Schabath MB, Ali-Osman F, Mata H, Wu X. Association between glutathione S-transferase P1 polymorphisms and lung cancer risk in Caucasians: a case–control study. Lung Cancer. 2003;40:25–32.PubMedCrossRef

Seidegard J, Vorachek WR, Pero RW, et al. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA. 1988;85(19):7293–7.PubMedCrossRef

Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30(6):445–600.PubMedCrossRef

Zhan P, Qian Q, Yu LK. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2013;5(1):40–7. doi:10.3978/j.issn.2072-1439.2013.01.02.PubMedCentralPubMed

Zhan P, Qian Q, Wan B, Yan TD, Yu LK. Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis. Cancer Res: Transl; 2013.

10.

Zhan P, Wang Q, Qian Q, Yu LK. Megestrol acetate in cancer patients with anorexia–cachexia syndrome: a meta-analysis. Transl Cancer Res. 2013;2(2):74–9. doi:10.3978/j.issn.2218-676X.2013.04.13.

11.

Zhan P, Wang Q, Qian Q, Yu LK. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials. Chin Clin Oncol. 2013. doi:10.3978/j.issn.2304-3865.2013.01.02.

12.

Zhan P, Qian Q, Yu LK. Prognostic significance of Vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis. Hepatobiliary Surg Nutr 2013 Jun 21. doi: 10.3978/j.issn.2304-3881.2013.06.06

13.

Zhan P, Qian Q, Yu LK. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr 2013 Jun 28. doi: 10.3978/j.issn.2304-3881.2013.06.07

14.

Zhan P, Ji YN, Yu LK. VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis. Transl Androl Urol. 2013. doi:10.3978/j.issn.2223-4683.2013.07.01.

15.

Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef

16.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

17.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

18.

Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7.

19.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315:629–34.PubMedCrossRef

20.

Deakin M, Elder J, Hendrickse C, et al. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric, and colorectal cancers. Carcinogenesis. 1996;17(4):881–4.PubMedCrossRef

21.

Park JY, Muscat JE, Ren Q, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev. 1997;6(10):791–7.PubMed

22.

Hung HC, Chuang J, Chien YC, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1 environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(11):901–5.PubMed

23.

Matthias C, Bockmühl U, Jahnke V, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics. 1998;8(2):91–100.PubMedCrossRef

24.

Jourenkova-Mironova N, Voho A, Bouchardy C, et al. Glutathione S-transferase GSTM1, GSTM3, GSTP1, and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer. 1999;81(1):44–8.PubMedCrossRef

25.

Sato M, Sato T, Izumo T, et al. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis. 1999;20(10):1927–31.PubMedCrossRef

26.

Katoh T, Kaneko S, Kohshi K, et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer. 1999;83(5):606–9.PubMedCrossRef

27.

Tanimoto K, Hayashi S, Yoshiga K, et al. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol. 1999;35(2):191–6.PubMedCrossRef

28.

Park LY, Muscat JE, Kaur T, et al. Comparison of GSTM polymorphisms and risk for oral cancer between African–Americans and Caucasians. Pharmacogenetics. 2000;10(2):123–31.PubMedCrossRef

29.

Nomura T, Noma H, Shibahara T, et al. Aldehyde dehydrogenase 2 and glutathione S-transferase M 1 polymorphisms in relation to the risk for oral cancer in Japanese drinkers. Oral Oncol. 2000;36(1):42–6.PubMedCrossRef

30.

Sreelekha TT, Ramadas K, Pandey M, et al. Genetic polymorphism of CYP1A1, GSTM1, and GSTT1 genes in Indian oral cancer. Oral Oncol. 2001;37(7):593–8.PubMedCrossRef

31.

Kietthubthew S, Sriplung H, Au WW. Genetic and environmental interactions on oral cancer in Southern Thailand. Environ Mol Mutagen. 2001;37(2):111–6.PubMedCrossRef

32.

Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3, and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis. 2002;23(5):803–7.PubMedCrossRef

33.

Hahn M, Hagedorn G, Kuhlisch E, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol. 2002;38(5):486–90.PubMedCrossRef

34.

Gronau S, Koenig-Greger D, Jerg M, et al. GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxification enzymes in squamous cell carcinoma of the oral cavity. Oral Dis. 2003;9(2):62–7.PubMedCrossRef

35.

Sikdar N, Paul RR, Roy B. Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer. 2004;109(1):95–101.PubMedCrossRef

36.

Xie H, Hou L, Shields PG, et al. Metabolic polymorphisms, smoking, and oral cancer in Puerto Rico. Oncol Res. 2004;14(6):315–20.PubMed

37.

Drummond SN, De Marco L, Noronha JC, et al. GSTM1 polymorphism and oral squamous cell carcinoma. Oral Oncol. 2004;40(1):52–5.PubMedCrossRef

38.

Majumder M, Sikdar N, Paul RR, et al. Increased risk of oral leukoplakia and cancer among mixed tobacco users carrying XRCC1 variant haplotypes and cancer among smokers carrying two risk genotypes: one on each of two loci, GSTM3, and XRCC1 (codon 280). Cancer Epidemiol Biomarkers Prev. 2005;14(9):2106–12.PubMedCrossRef

39.

Liu CJ, Chang CS, Lui MT, et al. Association of GST genotypes with age of onset and lymph node metastasis in oral squamous cell carcinoma. J Oral Pathol Med. 2005;34(8):473–7.PubMedCrossRef

40.

Huang P, An Y, Wu C, Meng X. GSTT1, GSTM1 polymorphisms, and oral and maxillofacial cancer. J Pract Oncol (Chin). 2006;21(1):39–42.

41.

Sugimura T, Kumimoto H, Tohnai I, et al. Gene–environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med. 2006;35(1):11–8.PubMedCrossRef

42.

Gattas GJ, de Carvalho MB, Siraque MS, et al. Genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 associated with head and neck cancer. Head Neck. 2006;28(9):819–26.PubMedCrossRef

43.

Sharma A, Mishra A, Das BC, et al. Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer. Neoplasma. 2006;53(4):309–15.PubMed

44.

Anantharaman D, Chaubal PM, Kannan S, et al. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1, and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Carcinogenesis. 2007;28(7):1455–62.PubMedCrossRef

45.

Cha IH, Park JY, Chung WY, et al. Polymorphisms of CYP1A1 and GSTM1 genes and susceptibility to oral cancer. Yonsei Med J. 2007;48(2):233–9.PubMedCentralPubMedCrossRef

46.

Varela-Lema L, Ruano-Ravina A, Juiz Crespo MA, et al. CYP1A1, mEH, and GSTM1 polymorphisms and risk of oral and pharyngeal cancer: a Spanish case–control study. J Oncol 2008:741310.

47.

Hatagima A, Costa EC, Marques CF, Koifman RJ, Boffetta P, Koifman S. Glutathione S-transferase polymorphisms and oral cancer: a case–control study in Rio de Janeiro. Brazil Oral Oncol. 2008;44(2):200–7.CrossRef

48.

Bathi RJ, Rao R, Mutalik S. GST null genotype and antioxidants: risk indicators for oral pre-cancer and cancer. Indian J Dent Res. 2009;20(3):298–303.PubMedCrossRef

49.

Amtha R, Ching CS, Zain R. GSTM1, GSTT1, and CYP1A1 polymorphisms and risk of oral cancer: a case–control study in Jakarta, Indonesia. Asian Pac J Cancer Prev. 2009;10(1):21–6.PubMed

50.

Chen MK, Tsai HT, Chung TT, et al. Glutathione S-transferase P1 and alpha gene variants: role in susceptibility and tumor size development of oral cancer. Head Neck. 2010;32(8):1079–87.PubMedCrossRef

51.

Sharma R, Ahuja M, Panda NK, et al. Combined effect of smoking and polymorphisms in tobacco carcinogen-metabolizing enzymes CYP1A1 and GSTM1 on the head and neck cancer risk in north Indians. DNA Cell Biol. 2010;29(8):441–8.PubMedCrossRef

52.

Cordero K, Espinoza I, Caceres D, Roco A, Miranda C, Squicciarini V, et al. Oral cancer susceptibility associated with the CYP1A1 and GSTM1 genotypes in Chilean individuals. Oncol Lett. 2010;1(3):549–53.PubMedCentralPubMed

53.

Lourenço GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1, and GSTT1 polymorphisms, tobacco and alcohol status, and risk of head and neck squamous cell carcinoma. Tumor Biol. 2011;32(6):1209–15.CrossRef

54.

Masood N, Kayani MA, Malik FA, Mahjabeen I, Baig RM, Faryal R. Genetic variation in carcinogen metabolizing genes associated with oral cancer in Pakistani population. Asian Pac J Cancer Prev. 2011;12(2):491–5.PubMed

55.

Shukla D, Dinesh Kale A, Hallikerimath S, Vivekanandhan S, Venkatakanthaiah Y. Genetic polymorphism of drug metabolizing enzymes (GSTM1 and CYP1A1) as risk factors for oral premalignant lesions and oral cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012;156(3):253–9.PubMedCrossRef

56.

Yadav DS, Devi TR, Ihsan R, Mishra AK, Kaushal M, Chauhan PS, et al. Polymorphisms of glutathione-S-transferase genes and the risk of aerodigestive tract cancers in the Northeast Indian population. Genet Test Mol Biomarkers. 2010;14(5):715–23.PubMedCrossRef

57.

Mondal R, Ghosh SK, Choudhury JH, Seram A, Sinha K, Hussain M, et al. Mitochondrial DNA copy number and risk of oral cancer: a report from Northeast India. PLoS One. 2013;8(3):e57771.PubMedCentralPubMedCrossRef

58.

Singh R, Haridas N, Shah F, Patel J, Shukla S, Patel P. Gene polymorphisms, tobacco exposure, and oral cancer susceptibility: a study from Gujarat. Oral Dis: West India; 2013. doi:10.1111/odi.12079.

59.

Hirschhorn JN, Lohmueller K, Byrne E. A comprehensive review of genetic association studies. Genet Med. 2002;4:45–61.PubMedCrossRef

60.

Zhang ZJ, Hao K, Shi R, Zhao G, Jiang GX, Song Y, et al. Glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null polymorphisms, smoking, and their interaction in oral cancer: a HuGE review and meta-analysis. Am J Epidemiol. 2011;15;173(8):847–57.CrossRef

61.

Zhou C, Zhou Y, Li J, Zhang Y, Jiang L, Zeng X, et al. Th ARG 194TRP polymorphism in the X-ray repair cross-complementing group 1 gene as a potential risk factor of oral cancer: a meta-analysis. Tohoku J Exp Med. 2009;219:43–51.PubMedCrossRef

62.

Niu Y, Hu Y, Wu M, Jiang F, Shen M, Tang C, et al. CYP2E1 Rsa I/Pst I polymorphism contributes to oral cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:607–12.PubMedCrossRef

63.

Zhuo XL, Li Q, Zhou Y, Cai L, Xiang ZL, Yuan W, et al. Study on TP53 codon 72 poly morphisms wit h oral carcinoma susceptibility. Arch Med Res. 2009;40:625–34.PubMedCrossRef

64.

Zhan P, Wang Q, Qian Q, Wei SZ, Yu LK. CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. J Exp Clin Cancer Res. 2011;20:30–99.

65.

Zhan P, Wang Q, Wei SZ, Wang J, Qian Q, Yu LK, et al. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case–control studies. J Thorac Oncol. 2010;5(9):1337–45.PubMedCrossRef

66.

Zhan P, Wang J, Zhang Y, Qiu LX, Zhao SF, Qian Q, et al. CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians. Lung Cancer. 2010;69(1):19–25.PubMedCrossRef

Titel: GSTM1 null polymorphisms and oral cancer risk: a meta-analysis
verfasst von: Su-Feng Zhao
Xu-Dong Yang
Ming-Xing Lu
Guo-Wen Sun
Yu-Xin Wang
Yin-Kai Zhang
Yu-Mei Pu
En-Yi Tang
Publikationsdatum: 01.01.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 1/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1037-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

GSTM1 null polymorphisms and oral cancer risk: a meta-analysis

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Antitumor activity of a polysaccharide fraction from Laminaria japonica on U14 cervical carcinoma-bearing mice

Association of Kaposi’s sarcoma-associated herpesvirus (KSHV) with bladder cancer in Croatian patients

SMAD4 is a potential prognostic marker in human breast carcinomas

Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions

A functional polymorphism in IL-1A gene is associated with a reduced risk of gastric cancer

XRCC1 R399Q polymorphism and risk of normal tissue injury after radiotherapy in breast cancer patients

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie